EML4-ALK fusion protein in Lung cancer cells enhances venous thrombogenicity through the pERK1/2-AP-1-tissue factor axis
-
Published:2023-11-08
Issue:1
Volume:57
Page:67-81
-
ISSN:1573-742X
-
Container-title:Journal of Thrombosis and Thrombolysis
-
language:en
-
Short-container-title:J Thromb Thrombolysis
Author:
Su Yanping, Yi Jiawen, Zhang Yuan, Leng Dong, Huang Xiaoxi, Shi Xinyu, Zhang YuhuiORCID
Abstract
Abstract
Background
Accumulating evidence links the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement to venous thromboembolism (VTE) in non-small cell lung cancer (NSCLC) patients. However, the corresponding mechanisms remain unclear.
Method
High-throughput sequencing analysis of H3122 human ALK-positive NSCLC cells treated with ALK inhibitor/ dimethyl sulfoxide (DMSO) was performed to identify coagulation-associated differential genes between EML4-ALK fusion protein inhibited cells and control cells. Sequentially, we confirmed its expression in NSCLC patients’ tissues and in the plasma of a subcutaneous xenograft mouse model. An inferior vena cava (IVC) ligation model was used to assess clot formation potential. Additionally, pathways involved in tissue factor (TF) regulation were explored in ALK-positive cell lines H3122 and H2228. Statistical significance was determined by Student t-test and one-way ANOVA using SPSS.
Results
Sequencing analysis identified a significant downregulation of TF after inhibiting EML4-ALK fusion protein activity in H3122 cells. In clinical NSCLC cases, TF expression was increased especially in ALK-positive NSCLC tissues. Meanwhile, H3122 and H2228 with high TF expression exhibited shorter plasma clotting time and higher TF activity versus ALK-negative H1299 and A549 in cell culture supernatant. Mice bearing H2228 tumor showed a higher concentration of tumor-derived TF and TF activity in plasma and the highest adjusted IVC clot weights. Limiting EML4-ALK protein phosphorylation downregulated extracellular regulated protein kinases 1/2 (ERK1/2)-activating the protein-1(AP-1) signaling pathway and thus attenuated TF expression.
Conclusion
EML4-ALK fusion protein may enhance venous thrombogenicity by regulating coagulation factor TF expression. There was potential involvement of the pERK1/2-AP-1 pathway in this process.
Funder
National Natural Science Foundation of China Clinical Research Incubation Project, Beijing Chao-Yang Hospital, Capital Medical University
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Hematology
Reference87 articles.
1. Ades S, Kumar S, Alam M, Goodwin A, Weckstein D, Dugan M, Ashikaga T, Evans M, Verschraegen C, Holmes CE (2015) Tumor oncogene (KRAS) status and risk of venous Thrombosis in patients with metastatic Colorectal cancer. J Thromb Haemost 13(6):998–1003 2. Unruh D, Schwarze SR, Khoury L, Thomas C, Wu MJ, Chen L, Chen R, Liu YX, Schwartz MA, Amidei C, Kumthekar P, Benjamin CG, Song K, Dawson C, Rispoli JM, Fatterpekar G, Golfinos JG, Kondziolka D, Karajannis M, Pacione D, Zagzag D, McIntyre T, Snuderl M (2016) Horbinski C.: Mutant IDH1 and thrombosis in gliomas. Acta Neuropathologica 132(6):917–930 3. Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant’Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M (2014) Grp Assoc Italiana Ric Canc: clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 124(7):1062–1069 4. Dou F, Zhang Y, Yi J, Zhu M, Zhang S, Zhang D, Zhang Y (2020) Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell Lung cancer: a prospective cohort study. Thromb Res 186:36–41 5. Su YP, Huo MR, Hua L, Zhang Y, Yi JW, Zhang S, Li J, Zhang YH (2021) Association of Venous Thromboembolism and early mortality in patients with newly diagnosed metastatic non-small cell Lung Cancer. Cancer Manage Res 13:4031–4040
|
|